Developing liquid formulations for the oral dosing of lipophilic drugs
This presentation focuses on the development of non-aqueous liquid formulations for highly lipophilic compounds. Experts from Pace® Life Sciences dive into lipophilicity and its chemical and biopharmaceutical consequences; formulation strategies to allow oral dosing in both pre-clinical and clinical studies; and analytical differences between these types of molecules.
However, please be aware that non-aqueous formulations for other routes of administration (e.g., injection or topical) will not be covered in this presentation.
Key Learning Objectives:
- The formulation challenges provided by highly lipophilic compounds can be managed using non-aqueous liquid vehicles
- The same drug/vehicle formulation can be administered directly into animals or filled into capsule shells for human dosing
- There can be some analytical challenges with this type of formulation
Who Should Attend:
- Formulation scientists
- Research and development (R&D) scientists
- Quality control scientists
- R&D managers
David Barnes, Ph.D., Vice President of Scientific Affairs
Dave has a degree in pharmacy and a Ph.D. from The School of Pharmacy, U. of London (“The Square”).
He has over thirty years of pharmaceutical product development experience, first with Pfizer in the UK, later with Pfizer in the USA and for the past 14 years as co-founder and Chief Scientist at Velesco Pharma Services.
Velesco’s focus on liquid and semi-solid products has provided much experience with and insights into the development of suspension formulations and the changes that occur as the compound progresses towards the marketplace.
In 2021 Velesco became a part of the Pace® Life Sciences laboratory network. Dave is now Vice President of Scientific Affairs at Pace® Life Sciences in Wixom, MI.